TJ Chao breaks down the black box warnings for ruxolitinib cream 1.5% and discusses the importance in communicating the specifics of these warnings to patients.
Lisa Swanson, MD, JCAD’s Section Editor of Pediatric Dermatology, shares her thoughts on new research evaluating maximum-use conditions for topical ruxolitinib cream in pediatric patients (2 to 11 years) with atopic dermatitis.
...